Unsatisfactory physicochemical properties of macromolecular drugs seriously hinder their
application in tumor immunotherapy. However, these problems can be effectively solved by …

Simple Summary In patients with acute myeloid leukemia (AML), genetic mutations can
cause cells to evade regulated cell death (RCD), resulting in excessive cell proliferation. The …

Background A recent breakthrough therapy combining the BCL‐2 inhibitor venetoclax with
hypomethylating agents (HMAs) targeting DNA methyltransferase has improved outcomes …

Myeloproliferative neoplasms (MPNs) are a group of clonal hematologic malignancies that
include polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF) …

BCL-2 inhibition has transformed the therapeutic landscape of acute myeloid leukemia
(AML) but is not curative for the majority of patients. Consequently, there has been growing …

Targeted protein degradation has emerged as an alternative therapy against cancer,
offering several advantages over traditional inhibitors. The new degrader drugs provide …

Exploiting the intrinsic apoptotic pathway in AML has emerged as a significant therapeutic
strategy. Specifically, BCL-2 inhibition with venetoclax (VEN) has transformed the …